Finance

Lists
DNPUF:OTCMKTS
Sumitomo Pharma Co Ltd
$9.27
0.00%
(0.00) 1D
Aug 25, 2:51:31 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNPUF...
Mkt. cap
742.54B
Avg. vol.
33.00
Volume
83.60K
52-wk high
$19.20
52-wk low
$8.40
Beta
0.38
Shares outstanding
449.20M
No. of employees
3K
Mkt. cap
742.54B
Avg. vol.
33.00
Volume
83.60K
52-wk high
$19.20
52-wk low
$8.40
Beta
0.38
Shares outstanding
449.20M
No. of employees
3K
Profile
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka. Wikipedia
About Sumitomo Pharma Co Ltd
CEO-
Employees3.12K
FoundedMay 14, 1897
HeadquartersOsaka, Osaka, Japan
SectorPharmaceutical industry
Websitesumitomo-pharma.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
119.12B
120.62B
105.55B
129.50B
Cost of goods sold
45.59B
55.44B
51.26B
61.41B
Cost of revenue
45.59B
55.44B
51.26B
61.41B
Research and development expenses
9.35B
10.35B
16.12B
11.43B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40.90B
42.94B
43.52B
39.24B
Operating expense
-1.04B
52.19B
110.09B
50.33B
Total operating expenses
44.55B
107.63B
161.36B
111.74B
Operating income
74.57B
13.00B
-55.81B
17.75B
Other non operating income
-
-
-1.64B
-
EBT including unusual items
80.87B
8.74B
-1.20B
18.30B
EBT excluding unusual items
80.87B
8.74B
-51.00B
18.30B
Income tax expense
-6.78B
-80.00M
-383.00M
1.30B
Effective tax rate
-8.39%
-0.92%
32.05%
7.09%
Other operating expenses
-51.30B
-1.10B
50.45B
-337.00M
Net income
87.65B
8.82B
-812.00M
17.00B
Net profit margin
73.58%
7.31%
-0.77%
13.13%
Earnings per share
-
-
-
-
Interest and investment income
5.11B
258.00M
4.64B
2.20B
Interest expense
-
-5.14B
-
-2.09B
Net interest expenses
5.11B
-4.88B
4.64B
107.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
79.85B
18.32B
-52.48B
22.65B
Gain or loss from assets sale
1.96B
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps